Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 2
What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?
Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 1
What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?
Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 2
What separates labs with truly connected, AI-ready data from those drowning in digital chaos?
Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 1
What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?
How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics
“Will this novel host replace CHO?” I hear this question often — and I want to be direct with you: I think it’s the wrong question.
Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)
Is CHO still the host of choice?
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2
Securing capital for biotech innovation has never been more challenging—or more crucial.
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.
Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 2
What happens between scientific discovery and clinical trials?
Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 1
Picture the difference between a “drug” and a true “product”.